Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00366288 · ClinicalTrials.gov registry record

Study Evaluating PAZ-417 in Healthy Young/Elderly

A clinical trial, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.

Completed
Registry status
56
Enrollment target

NCT00366288 is a clinical trial that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 56 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00366288 has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.

COMPLETED
Registry status
56 participants
Enrollment target

Study Summary

This study is to evaluate the safety and tolerability of single, ascending doses of PAZ-417 in healthy young and healthy elderly subjects. The effect of a high fat meal on the metabolism of PAZ-417 will also be studied, along with blood levels of PAZ-417 . Changes in cognitive function will be assessed.

Interventions

  • DRUG PAZ-417

Trial Details

FieldValue
Enrollment Target 56 participants
Start Date 2006-07
Est. Completion 2008-03

What the Registry Record Tells You About NCT00366288

The ClinicalTrials.gov registry entry for NCT00366288 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which PAZ-417 is the first listed.

NCT00366288 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00366288 about?

NCT00366288 is a clinical study titled "Study Evaluating PAZ-417 in Healthy Young/Elderly". This study is to evaluate the safety and tolerability of single, ascending doses of PAZ-417 in healthy young and healthy elderly subjects. The effect of a high fat meal on the metabolism of PAZ-417 will also be studied, along with blood levels of PAZ-417 . Changes in cognitive function will be asses...

What is the current status of trial NCT00366288?

This trial is currently completed. The enrollment target is 56 participants. The study started on 2006-07. Estimated completion is 2008-03.

What interventions are being tested in trial NCT00366288?

The interventions under investigation include: PAZ-417 (DRUG).

Who is sponsoring clinical trial NCT00366288?

This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.